EDMONTON, Alberta, Oct. 16, 2024 – PRESS RELEASE – Aurora Cannabis Inc., a Canadian-based global leader in medical cannabis, in conjunction with MedReleaf Australia, announced an enhanced product range of premium medical cannabis oil in Australia. This expansion reinforces Aurora's dedication to providing high-quality, innovative cannabis solutions to patients around the world. Now available for physicians to prescribe, the new cannabis oils include a variety of cannabinoid ratios to suit diverse patient needs.
The new cannabis oil products include Aurora THC 25 (Sativa) in a 30-milliliter bottle, Aurora THC 25 (Indica) in a 30-milliliter bottle, Aurora 12.5:12.5 oil in a 30-milliliter bottle, Aurora 50:50 oil in a 30-milliliter bottle, and Aurora 10:100 oil in a 30-milliliter bottle. Each formulation offers varying cannabinoid ratios to support personalized treatment options for patients.
"We are thrilled to bring this enhanced range of cannabis oil products to the Australian market," said Andre Jerome, executive vice president of Global Business Development at Aurora. "Our mission is to offer health care providers and their patients a broader selection of treatment options that meet their various medical needs. By expanding our product portfolio, we continue to demonstrate our commitment to advancing patient care through high-quality, science-driven cannabis solutions."
The newly available oils are developed and manufactured at Aurora's Canadian TGA and EU GMP-certified facility, adding to the expanding lineup with increased cannabinoid variety. The new products allow doctors to tailor treatments more precisely, enhancing patient care. These offerings are another step forward in MedReleaf Australia's mission to expand access to quality medical cannabis options for patients across the country.
Key features of Aurora's new cannabis oil products include:
· Comprehensive Cannabinoid Profiles: Designed to provide targeted and effective relief with a variety of THC and CBD ratios.
· High Standards of Quality and Safety: Manufactured in TGA-GMP-certified facilities, adhering to rigorous quality control measures.
· Broad Selection: Wide range of unique oil formulations, allowing for customized patient care.
For additional information, health care professionals can contact MedReleaf Australia's clinical support team or visit their website: www.medreleafaustralia.com.au.
